The firm said that in its product pipeline in 2019 it focused on organ transplant and lung health, involving use of its multiplexed research-use TORdx Lung tests.
Pressure associated with competition and reimbursement may erode GenMark's market share and product pricing, JP Morgan said.
Proscia said that its partnership with Johns Hopkins, which aims to accelerate research breakthroughs and improve patient outcomes, is one among a number of its recent pathology-related engagements.
Researchers at Baylor College of Medicine and Columbia University found that almost all blood samples from pregnant women tested contained several trophoblasts.
In a proof-of-principle study, Ohio State University researchers compared the nanopore sequencing assay to short-read sequencing and capillary electrophoresis.
On the heels of receiving CE marking, the firm is engaging with global distributors and preparing a submission to the FDA for US clearance.
The firm also said it is contemplating selling its therapeutics division, and appointed David Bench as its new CFO.
The firm has entered the market in Africa with a new collaboration in Ghana. It is also developing instrument-agnostic STI and liquid biopsy tests.
The firm said that after its device is placed on the upper arm, blood collection usually takes between two and three minutes following the press of a button.
Invitae will provide genetic testing for 109 genes associated with the conditions, while BioMarin will provide financial support for the program.